Enlivex Therapeutics Gets Green Light for Phase II COVID-19 Trial
Ticker: ENLV · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, covid-19, drug-development
TL;DR
Enlivex's Allocetra gets Phase II trial approval in Denmark for severe COVID-19.
AI Summary
On September 26, 2024, Enlivex Therapeutics Ltd. announced that the Danish Medicines Agency has authorized the initiation of the Phase II stage of its clinical trial for Allocetra. This trial will investigate Allocetra's efficacy in treating patients with severe COVID-19.
Why It Matters
Regulatory approval for a Phase II trial is a significant step in drug development, indicating promising early results and moving Enlivex closer to potentially offering a new treatment for severe COVID-19.
Risk Assessment
Risk Level: medium — Clinical trial progression is subject to inherent risks, including efficacy and safety outcomes, regulatory hurdles, and market acceptance.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Danish Medicines Agency (company) — Regulatory body authorizing trial
- Allocetra (drug) — Investigational therapy
- September 26, 2024 (date) — Date of announcement
FAQ
What is the purpose of the Phase II trial authorized by the Danish Medicines Agency?
The Phase II trial will investigate the efficacy of Enlivex's Allocetra in treating patients with severe COVID-19.
Which regulatory body authorized the Phase II trial?
The Danish Medicines Agency authorized the initiation of the Phase II stage.
What is the name of the drug being investigated?
The drug being investigated is Allocetra.
When was this authorization announced?
The announcement was made on September 26, 2024.
What is Enlivex Therapeutics Ltd.'s country of incorporation?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-09-26 08:32:02
Filing Documents
- ea0215700-6k_enlivex.htm (6-K) — 14KB
- ea021570001ex99-1_enlivex.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-081980.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: September 26, 2024 2